既往局部治疗对转移性去势抵抗性前列腺癌一线雄激素受体轴靶向治疗反应的影响:COU-AA-302 试验的二次分析
本研究为 COU-AA-302 试验的探索性分析,纳入 1053 例多西他赛初治的转移性去势抵抗性前列腺癌患者,其中 64%(n=669)曾接受前列腺局部治疗。使用 Cox 比例风险模型比较一线阿比特龙联合泼尼松在不同局部治疗史患者中的时变效应,未发现放射学无进展生存期和总生存期的治疗效应存在显著异质性。
要点
- 既往局部治疗不影响一线阿比特龙对多西他赛初治 mCRPC 的疗效。
- 既往局部治疗与总生存期显著改善相关(平均 HR 0.72)。
- 不同局部治疗史患者的治疗效应异质性无统计学显著性。
核心结论
- 一线阿比特龙联合泼尼松在多西他赛初治 mCRPC 中的疗效不因既往是否接受前列腺局部治疗而显著改变。
- 既往局部治疗与总生存期显著改善相关(平均 HR 0.72 [95%CI 0.59-0.89])。
- 需进一步研究探索既往局部治疗与更优总生存期关联的潜在机制。
研究设计与样本
- COU-AA-302 试验的探索性分析。
- COU-AA-302 为多中心双盲 3 期随机对照试验,纳入无至轻度症状的 mCRPC 患者,随机接受阿比特龙联合泼尼松或安慰剂联合泼尼松。
- 共 1053 例符合条件患者,64%(n=669)曾接受局部治疗。
- 采用 Cox 比例风险模型比较一线阿比特龙的时变效应,使用网格搜索确定切点为 rPFS 6 个月和 OS 36 个月。
- 使用加权 Cox 回归模型确定既往局部治疗与生存的校正关联。
主要发现
- 既往局部治疗组 rPFS 的 HR 在 ≤6 个月为 0.36(95%CI 0.27-0.49),>6 个月为 0.64(95%CI 0.49-0.83);无局部治疗组 ≤6 个月为 0.37(95%CI 0.26-0.55),>6 个月为 0.72(95%CI 0.50-1.03)。
- 既往局部治疗组 OS 的 HR 在 ≤36 个月为 0.88(95%CI 0.71-1.10),>36 个月为 0.76(95%CI 0.52-1.11);无局部治疗组 ≤36 个月为 0.78(95%CI 0.60-1.01),>36 个月为 0.55(95%CI 0.30-0.99)。
- 阿比特龙对前列腺癌子量表评分变化(交互作用 P=0.4)、试验结局指数(交互作用 P=0.8)和 FACT-P 总分(交互作用 P=0.6)的治疗效应不因既往局部治疗而存在差异的充分证据。
- 既往局部治疗与总生存期显著改善相关(平均 HR 0.72 [95%CI 0.59-0.89])。
关键数值与推荐
- rPFS 切点为 6 个月,OS 切点为 36 个月。
- 既往局部治疗组 rPFS HR:≤6 个月 0.36(95%CI 0.27-0.49),>6 个月 0.64(95%CI 0.49-0.83)。
- 无局部治疗组 rPFS HR:≤6 个月 0.37(95%CI 0.26-0.55),>6 个月 0.72(95%CI 0.50-1.03)。
- 既往局部治疗组 OS HR:≤36 个月 0.88(95%CI 0.71-1.10),>36 个月 0.76(95%CI 0.52-1.11)。
- 无局部治疗组 OS HR:≤36 个月 0.78(95%CI 0.60-1.01),>36 个月 0.55(95%CI 0.30-0.99)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为探索性分析。
- 需进一步研究探索既往局部治疗与更优总生存期关联的潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men with localized prostate cancer are often treated with local therapy (LT). However, a proportion of these patients will eventually develop recurrence and progression requiring systemic therapy. Whether primary LT affects the response to this subsequent systemic treatment is unclear. OBJECTIVE: We investigated whether the receipt of prior prostate-directed LT influenced the response to first-line systemic therapy and survival in docetaxel-naïve metastatic castrate-resistant prostate cancer (mCRPC) patients. DESIGN, SETTING, AND PARTICIPANTS: This is an exploratory analysis of the COU-AA-302 trial, a multicentric double-blinded phase 3 randomized controlled trial in which mCRPC patients with no to mild symptoms were randomized to receive abiraterone plus prednisone or placebo plus prednisone. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We compared the time-varying effects of first-line abiraterone in patients with and without prior LT using a Cox proportional hazard model. The cut points were chosen using grid search, and were 6 and 36 mo for radiographic progression-free survival (rPFS) and overall survival (OS), respectively. We also investigated whether there was any difference in treatment effect on score change (relative to baseline) in various patient-reported outcomes (measured by Functional Assessment of Cancer Therapy-Prostate [FACT-P]) over time depending on the receipt of prior LT. The adjusted association of prior LT with survival was determined using weighted Cox regression models. RESULTS AND LIMITATIONS: Among 1053 eligible patients, 64% (n = 669) received prior LT. We did not find any statistically significant heterogeneity of time-dependent treatment effect from abiraterone on rPFS in patients with (hazard ratio [HR]: 0.36 [95% confidence interval: 0.27-0.49] at ≤6 mo; 0.64 [0.49-0.83] at >6 mo) or without (HR: 0.37 [0.26-0.55] at ≤6 mo; 0.72 [0.50-1.03] at >6 mo) prior LT. Similarly, there was no significant heterogeneity in time-dependent treatment effect on OS with (HR: 0.88 [0.71-1.10] at ≤36 mo; 0.76 [0.52-1.11] at >36 mo) or without (0.78 [0.60-1.01] at ≤36 mo; 0.55 [0.30-0.99] at >36 mo) prior LT. We did not find sufficient evidence of a difference in treatment effect from abiraterone on score change over time in prostate cancer subscale (interaction p = 0.4), trial outcome index (interaction p = 0.8), and FACT-P total score (interaction p = 0.6) depending on the receipt of prior LT. Receipt of prior LT was associated with a significant improvement in OS (average HR: 0.72 [0.59-0.89]). CONCLUSIONS: This study demonstrates that the efficacy of first-line abiraterone and prednisone in docetaxel-naïve mCRPC do not vary significantly based on the receipt of prior prostate-directed LT. Further studies are needed to explore the plausible mechanisms of the association of prior LT with superior OS. PATIENT SUMMARY: This secondary analysis of the COU-AA-302 trial suggests that survival benefits and temporal changes in quality of life with first-line abiraterone in docetaxel-naïve mCRPC do not differ significantly among patients who received versus those who did not receive prior prostate-directed local therapy.
引用
- Roy S, Sun Y, Morgan SC, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol. 2023. PMID: 36894488. doi:10.1016/j.eururo.2023.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。